Expression of miR‑26b in ovarian carcinoma tissues and its correlation with clinicopathology

Lu,Jianjun; Zhang,Wei; Ding,Yang; Li,Xiang; Song,Jiandong

doi:10.3892/ol.2019.10117

Expression of miR‑26b in ovarian carcinoma tissues and its correlation with clinicopathology

Authors:
- Jianjun Lu
- Wei Zhang
- Yang Ding
- Xiang Li
- Jiandong Song
View Affiliations

Affiliations: Department of Gynaecology and Obstetrics, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia 010059, P.R. China
Published online on: March 5, 2019 https://doi.org/10.3892/ol.2019.10117
Pages: 4417-4422
Copyright: © Lu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The expression of microRNA (miR)‑26b in ovarian carcinoma tissues, its correlation with clinicopathology, and its effect on diagnostic value and prognosis of ovarian cancer was investigated. A total of 74 patients with ovarian cancer (the study group) and 30 patients with benign ovarian tumors (the control group) in the Affiliated Hospital of Inner Mongolia Medical University from July 2011 to June 2013 were retrospectively analyzed. The expression of miR‑26b in ovarian carcinoma tissues was detected by fluorescence reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and the correlation between the expression of miR‑26b and the pathological features of ovarian carcinoma tissues and prognosis of patients was analyzed. The expression level of miR‑26b in the study group (0.28±0.07) was significantly lower than that in the control group (0.54±0.11; P<0.050). There was no significant correlation between miR‑26b expression and age, tumor type, exercise habit, smoking habit of patients with ovarian cancer (P>0.050), but there was close correlation between the miR‑26b expression and lymph node metastasis, differentiation degree and pathological stage of patients with ovarian cancer (P<0.001). ROC curve showed that the area under curve (AUC) was 0.839, and when the maximum cut‑off value was 0.815, the sensitivity and specificity of miR‑26b in diagnosing the ovary was 84.932% and 77.936%, respectively. The 5‑year overall survival rate in the low‑expression group (61.54%) was significantly lower than that in the high‑expression group (84.85; P=0.028). miR‑26b is under‑expressed in the ovary and has a close relationship with pathological stage, differentiation degree, and lymph node metastasis of ovarian cancer, which indicates that miR‑26b is involved in the occurrence and development of ovarian cancer and is expected to be an effective indicator for treatment and diagnosis of ovarian cancer and the prognosis of patients.

View Figures

View References

1	Jaaback K and Johnson N: Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 1:CD0053402006.
2	Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, et al: ENGOT-OV16/NOVA investigators: Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 375:2154–2164. 2016. View Article : Google Scholar : PubMed/NCBI
3	Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, Amso NN, Apostolidou S, Benjamin E, Cruickshank D, et al: Ovarian cancer screening and mortality in the UK collaborative trial of ovarian cancer screening (UKCTOCS): A randomised controlled trial. Lancet. 387:945–956. 2016. View Article : Google Scholar : PubMed/NCBI
4	Oikonomopoulou K, Li L, Zheng Y, Simon I, Wolfert RL, Valik D, Nekulova M, Simickova M, Frgala T and Diamandis EP: Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel. Br J Cancer. 99:1103–1113. 2008. View Article : Google Scholar : PubMed/NCBI
5	Zhang H, Liu T, Zhang Z, Payne SH, Zhang B, McDermott JE, Zhou JY, Petyuk VA, Chen L, Ray D, et al: CPTAC investigators: Integrated proteogenomic characterization of human high-grade serous ovarian cancer. Cell. 166:755–765. 2016. View Article : Google Scholar : PubMed/NCBI
6	Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN, et al: Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of gynecologic oncology and American society of clinical oncology clinical practice guideline. Gynecol Oncol. 143:3–15. 2016. View Article : Google Scholar : PubMed/NCBI
7	Zhao Z, Yang Y, Zeng Y and He M: A microfluidic ExoSearch chip for multiplexed exosome detection towards blood-based ovarian cancer diagnosis. Lab Chip. 16:489–496. 2016. View Article : Google Scholar : PubMed/NCBI
8	Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, Garber JE, Chowdhury D, Wu CJ, D'Andrea AD, et al: Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 7:13587–13598. 2016. View Article : Google Scholar : PubMed/NCBI
9	Au Yeung CL, Co NN, Tsuruga T, Yeung TL, Kwan SY, Leung CS, Li Y, Lu ES, Kwan K, Wong KK, et al: Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun. 7:111502016. View Article : Google Scholar : PubMed/NCBI
10	Bracken CP, Scott HS and Goodall GJ: A network-biology perspective of microRNA function and dysfunction in cancer. Nat Rev Genet. 17:719–732. 2016. View Article : Google Scholar : PubMed/NCBI
11	Rupaimoole R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
12	Christopher AF, Kaur RP, Kaur G, Kaur A, Gupta V and Bansal P: MicroRNA therapeutics: Discovering novel targets and developing specific therapy. Perspect Clin Res. 7:68–74. 2016. View Article : Google Scholar : PubMed/NCBI
13	Li D, Wei Y, Wang D, Gao H and Liu K: MicroRNA-26b suppresses the metastasis of non-small cell lung cancer by targeting MIEN1 via NF-κB/MMP-9/VEGF pathways. Biochem Biophys Res Commun. 472:465–470. 2016. View Article : Google Scholar : PubMed/NCBI
14	John Clotaire DZ, Zhang B, Wei N, Gao R, Zhao F, Wang Y, Lei M and Huang W: MiR-26b inhibits autophagy by targeting ULK2 in prostate cancer cells. Biochem Biophys Res Commun. 472:194–200. 2016. View Article : Google Scholar : PubMed/NCBI
15	Burges A and Schmalfeldt B: Ovarian cancer: Diagnosis and treatment. Dtsch Arztebl Int. 108:635–641. 2011.PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Wentzensen N, Poole EM, Trabert B, White E, Arslan AA, Patel AV, Setiawan VW, Visvanathan K, Weiderpass E, Adami HO, et al: Ovarian cancer risk factors by histologic subtype: An analysis from the ovarian cancer cohort consortium. J Clin Oncol. 34:2888–2898. 2016. View Article : Google Scholar : PubMed/NCBI
18	Romagnolo C, Leon AE, Fabricio ASC, Taborelli M, Polesel J, Del Pup L, Steffan A, Cervo S, Ravaggi A, Zanotti L, et al: HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study. Gynecol Oncol. 141:303–311. 2016. View Article : Google Scholar : PubMed/NCBI
19	Morgan RJ Jr, Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Behbakht K, Chen LM, Copeland L, Crispens MA, DeRosa M, Dorigo O, et al: Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 14:1134–1163. 2016. View Article : Google Scholar : PubMed/NCBI
20	Inamura K and Ishikawa Y: MicroRNA in lung cancer: Novel biomarkers and potential tools for treatment. J Clin Med. 5:362016. View Article : Google Scholar
21	Saadatpour L, Fadaee E, Fadaei S, Nassiri Mansour R, Mohammadi M, Mousavi SM, Goodarzi M, Verdi J and Mirzaei H: Glioblastoma: Exosome and microRNA as novel diagnosis biomarkers. Cancer Gene Ther. 23:415–418. 2016. View Article : Google Scholar : PubMed/NCBI
22	Li Z, Ma YY, Wang J, Zeng XF, Li R, Kang W and Hao XK: Exosomal microRNA-141 is upregulated in the serum of prostate cancer patients. Onco Targets Ther. 9:139–148. 2015.PubMed/NCBI
23	Sun C, Li S, Yang C, Xi Y, Wang L, Zhang F and Li D: MicroRNA-187-3p mitigates non-small cell lung cancer (NSCLC) development through down-regulation of BCL6. Biochem Biophys Res Commun. 471:82–88. 2016. View Article : Google Scholar : PubMed/NCBI
24	Rubiś P, Totoń-Żurańska J, Wiśniowska-Śmiałek S, Holcman K, Kołton-Wróż M, Wołkow P, Wypasek E, Natorska J, Rudnicka-Sosin L, Pawlak A, et al: Relations between circulating microRNAs (miR-21, miR-26, miR-29, miR-30 and miR-133a), extracellular matrix fibrosis and serum markers of fibrosis in dilated cardiomyopathy. Int J Cardiol. 231:201–206. 2017. View Article : Google Scholar : PubMed/NCBI
25	Li Y, Sun Z, Liu B, Shan Y, Zhao L and Jia L: Tumor-suppressive miR-26a and miR-26b inhibit cell aggressiveness by regulating FUT4 in colorectal cancer. Cell Death Dis. 8:e28922017. View Article : Google Scholar : PubMed/NCBI
26	Shi L, Yin W, Zhang Z and Shi G: Down-regulation of miR-26b induces cisplatin resistance in nasopharyngeal carcinoma by repressing JAG1. FEBS Open Bio. 6:1211–1219. 2016. View Article : Google Scholar : PubMed/NCBI
27	Liu J, Tu F, Yao W, Li X, Xie Z, Liu H, Li Q and Pan Z: Conserved miR-26b enhances ovarian granulosa cell apoptosis through HAS2-HA-CD44-Caspase-3 pathway by targeting HAS2. Sci Rep. 6:211972016. View Article : Google Scholar : PubMed/NCBI